X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs J.B.CHEMICALS - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB J.B.CHEMICALS DR. REDDYS LAB/
J.B.CHEMICALS
 
P/E (TTM) x 27.7 17.1 162.2% View Chart
P/BV x 3.4 2.3 147.7% View Chart
Dividend Yield % 0.8 0.2 460.3%  

Financials

 DR. REDDYS LAB   J.B.CHEMICALS
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
J.B.CHEMICALS
Mar-16
DR. REDDYS LAB/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs2,788318 876.5%   
Low Rs1,902200 953.2%   
Sales per share (Unadj.) Rs860.8148.0 581.7%  
Earnings per share (Unadj.) Rs57.119.1 299.0%  
Cash flow per share (Unadj.) Rs122.023.9 509.5%  
Dividends per share (Unadj.) Rs20.000.50 4,000.0%  
Dividend yield (eoy) %0.90.2 441.5%  
Book value per share (Unadj.) Rs757.7128.9 587.6%  
Shares outstanding (eoy) m165.9184.82 195.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.7 155.8%   
Avg P/E ratio x41.113.6 303.0%  
P/CF ratio (eoy) x19.210.8 177.8%  
Price / Book Value ratio x3.12.0 154.2%  
Dividend payout %35.02.6 1,337.7%   
Avg Mkt Cap Rs m389,03421,951 1,772.3%   
No. of employees `00023.52.7 860.4%   
Total wages/salary Rs m32,1491,841 1,746.1%   
Avg. sales/employee Rs Th6,070.84,590.9 132.2%   
Avg. wages/employee Rs Th1,366.6673.4 202.9%   
Avg. net profit/employee Rs Th402.5592.1 68.0%   
INCOME DATA
Net Sales Rs m142,81012,551 1,137.8%  
Other income Rs m1,552542 286.6%   
Total revenues Rs m144,36213,093 1,102.6%   
Gross profit Rs m23,5122,055 1,144.3%  
Depreciation Rs m10,772412 2,612.0%   
Interest Rs m78896 823.4%   
Profit before tax Rs m13,5042,088 646.7%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380469 933.7%   
Profit after tax Rs m9,4681,619 584.9%  
Gross profit margin %16.516.4 100.6%  
Effective tax rate %32.422.5 144.4%   
Net profit margin %6.612.9 51.4%  
BALANCE SHEET DATA
Current assets Rs m104,9847,778 1,349.8%   
Current liabilities Rs m68,9384,358 1,581.9%   
Net working cap to sales %25.227.2 92.6%  
Current ratio x1.51.8 85.3%  
Inventory Days Days7455 136.0%  
Debtors Days Days10480 129.4%  
Net fixed assets Rs m104,3855,713 1,827.2%   
Share capital Rs m830170 489.4%   
"Free" reserves Rs m124,88610,547 1,184.1%   
Net worth Rs m125,71610,937 1,149.4%   
Long term debt Rs m25,0890-   
Total assets Rs m225,44315,574 1,447.6%  
Interest coverage x18.122.8 79.5%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.60.8 78.6%   
Return on assets %4.511.0 41.3%  
Return on equity %7.514.8 50.9%  
Return on capital %9.720.0 48.6%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m72,6236,169 1,177.2%   
Fx outflow Rs m18,9161,285 1,471.9%   
Net fx Rs m53,7074,884 1,099.7%   
CASH FLOW
From Operations Rs m18,0301,397 1,290.9%  
From Investments Rs m-14,883-320 4,646.6%  
From Financial Activity Rs m-4,440-1,196 371.3%  
Net Cashflow Rs m-1,236-102 1,208.2%  

Share Holding

Indian Promoters % 25.5 55.4 46.0%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 5.4 3.4 159.3%  
FIIs % 35.3 3.9 905.1%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 37.0 41.4%  
Shareholders   75,885 30,437 249.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Dec 14, 2018 03:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS